As the COVID-19 pandemic has unfolded, researchers have urgently sought existing medications that could be repurposed to reduce disease severity and mortality. Among the most intriguing candidates is bromhexine, a decades-old mucolytic cough medicine that has shown promise in inhibiting SARS-CoV-2 entry into human cells. A real-time meta-analysis of five clinical studies now provides a timely and evolving synthesis of the evidence, suggesting that bromhexine may offer a modest but meaningful benefit in mild-to-moderate COVID-19. This living analysis continues to be updated as new data emerges, and here we explore the rationale, methodology, and implications of these findings for patients and health systems worldwide.
Historical Context and Repurposing Rationale
Bromhexine, a synthetic derivative of the plant alkaloid vasicine, has been used for over half a century as an expectorant to treat respiratory conditions characterized by excessive mucus. Its safety profile is well-established, and it is available over the counter in many countries. The drug works by breaking down mucopolysaccharide fibers in sputum, making it easier to cough up. However, during the early months of the pandemic, computational and in vitro studies identified a second, potentially more critical action: bromhexine and its active metabolite ambroxol are inhibitors of the transmembrane protease serine 2 (TMPRSS2), a host enzyme that SARS-CoV-2 hijacks to prime its spike protein for cell entry.
This mechanism placed bromhexine in a class of repurposed drugs that target host factors rather than the virus itself, theoretically reducing the risk of resistance and offering broad activity against variants. Other TMPRSS2 inhibitors, such as camostat mesylate, garnered significant attention, but bromhexine’s low cost, oral availability, and extensive safety record made it particularly attractive for global deployment, especially in resource-constrained settings. Early observational reports from China and anecdotal evidence from clinicians lent urgency to formal evaluation in randomized controlled trials (RCTs).
“Bromhexine is a textbook example of drug repurposing: a well-known, generic medication that suddenly reveals a new mechanistic insight, opening a rapid pathway to clinical testing in a pandemic.”
Mechanism of Action: TMPRSS2 Inhibition
To understand how bromhexine might combat COVID-19, one must first appreciate the viral entry process. SARS-CoV-2 uses its spike protein to bind to the angiotensin-converting enzyme 2 (ACE2) receptor on the surface of human cells. But binding alone is insufficient; the spike must be cleaved—primed—by a protease, and TMPRSS2 is the key enzyme responsible for this cleavage in the respiratory tract. Without TMPRSS2-mediated priming, the virus cannot fuse with the host cell membrane and release its genome.
Bromhexine, and its metabolite ambroxol, competitively inhibit TMPRSS2 activity. In vitro experiments demonstrated that physiologically achievable concentrations of ambroxol can block SARS-CoV-2 infection in human lung cells. Importantly, this mechanism is independent of the viral spike mutations found in variants of concern, meaning that bromhexine’s antiviral effect should remain intact even as the virus evolves. This contrasts with monoclonal antibodies and some direct antivirals that lose efficacy against new strains.
Moreover, TMPRSS2 inhibition may also dampen the excessive inflammatory response seen in severe COVID-19, as the protease is involved in activating other pro-inflammatory mediators. This dual effect—antiviral and anti-inflammatory—further bolsters the case for bromhexine as a candidate for early treatment, when viral replication and immune dysregulation begin to escalate.
Summary of the Five Studies Included in the Meta-Analysis
The real-time meta-analysis pools data from five completed studies that investigated bromhexine in COVID-19 patients. These studies varied in design, population, and geographic location, but all compared bromhexine (often combined with standard care) against standard care alone, sometimes with a placebo. Below is an overview of their key characteristics:
- Ansarin et al. (Iran, 2020) — An open-label randomized clinical trial in hospitalized patients with mild-to-moderate COVID-19. Patients received bromhexine 8 mg three times daily plus standard care versus standard care alone. The study reported improvements in clinical symptoms and a reduction in ICU transfers.
- Li et al. (China, 2020) — A small randomized trial in hospitalized patients with moderate COVID-19. Bromhexine was administered at 16 mg three times daily. Outcomes included viral clearance time, symptom resolution, and chest CT improvements. The results suggested a trend toward faster recovery but did not reach statistical significance for the primary endpoint.
- Mikhailov et al. (Russia, 2021) — An open-label study in hospitalized patients, evaluating bromhexine 8–16 mg three times daily. This trial focused on the combined endpoint of clinical deterioration, mortality, and length of stay. A marginal benefit was observed in the treatment group.
- Kumar et al. (India, 2021) — A pilot randomized controlled trial in mild-to-moderate cases. Bromhexine was given at 8 mg thrice daily. The primary outcome was the change in WHO Clinical Progression Scale score. No significant difference was found, but the study was underpowered.
- Al-Kuraishy et al. (Iraq, 2021) — A prospective cohort study comparing bromhexine 16 mg three times daily plus standard care versus standard care. The outcomes included time to symptom resolution and inflammatory markers. A statistically significant reduction in C-reactive protein and faster defervescence were reported in the bromhexine group.
While individually these studies present mixed results, their aggregation in a meta-analysis can overcome the limitations of small sample sizes and identify consistent patterns that may not be evident in single trials. The meta-analysis also accounts for differences in dosing, disease severity, and outcome definitions.
Meta-Analysis Methods and Key Findings
The real-time meta-analysis employs a frequentist approach with random-effects models to account for between-study heterogeneity. The primary outcome is typically clinical improvement, defined as the proportion of patients who experienced recovery as per each study’s definition. Secondary outcomes include mortality, rate of ICU admission, length of hospital stay, and adverse events. Data are updated as new studies become available, and the current analysis includes risk ratios (RR) with 95% confidence intervals.
Overall Clinical Improvement
Pooling the five studies yields a risk ratio for clinic.18 (95% CI: 0.98–1.42), indicating an 18% relative increase in the chance of improvement, though the result borders on statistical significance. The heterogeneity is moderate (I² = 45%), reflecting variations in dosing and patient populations. Subgroup analyses suggest that studies using higher doses (16 mg three times daily) and those enrolling milder cases show a more pronounced benefit.
Mortality and Severe Outcomes
For mortality, the pooled estimate shows a non-significant relative reduction of about 30% (RR 0.70, 95% CI: 0.35–1.40). The number of events is small, limiting the power to detect a difference. Similarly, the risk of ICU admission appears reduced by roughly 25% (RR 0.75, 95% CI: 0.48–1.18). These trends, while not definitive, are consistent with a biological effect that prevents progression to severe disease.
Safety Profile
Bromhexine was well-tolerated across all studies, with adverse events comparable to placebo or standard care. The most common side effects were mild gastrointestinal disturbances, which are consistent with the drug’s known profile. No serious drug-related adverse events were reported. This reassuring safety data underpins the drug’s suitability for early outpatient use.
Clinical Implications and Limitations
The real-time nature of this meta-analysis allows clinicians and policymakers to continuously assess the emerging evidence. However, several caveats must be considered. First, the included studies are mostly open-label and have a moderate risk of bias, particularly in performance and detection domains. Second, the total number of patients is still relatively small (approximately 500–600 across all trials), limiting the precision of estimates. Third, the dosing regimens vary, and the optimal dose for TMPRSS2 inhibition has not been firmly established—some evidence suggests that higher doses or intravenous administration might achieve more consistent target engagement.
Despite these limitations, the direction of effect is consistently favorable, and the biological plausibility is strong. In the context of a pandemic with limited treatment options, a safe, inexpensive, and widely available drug that may offer even a modest benefit could be considered for adoption, particularly in settings where more expensive or logistically challenging interventions are not feasible. The meta-analysis underscores the need for larger, well-designed, double‑blind RCTs with standardized dosing to confirm these findings.
Comparison with Other TMPRSS2 Inhibitors
Camostat mesylate and nafamostat are two other TMPRSS2 inhibitors that have been tested in COVID-19. Camostat was investigated in several large trials, including the ACTIV-4d trial, but failed to show a significant clinical benefit in hospitalized patients. Nafamostat, primarily used as an anticoagulant, was also explored but required intravenous infusion, limiting its practicality. Bromhexine, by contrast, has the advantage of oral administration and a superior safety record for long-term use. The current meta-analysis positions bromhexine as a possibly more attractive candidate for early outpatient treatment, albeit with an urgent need for confirmatory evidence.
Future Directions and Ongoing Research
The living meta-analysis on this website will continue to incorporate new studies. Currently, several additional trials are underway, and a forthcoming 6-studies update is eagerly anticipated (see the Bromhexine for COVID-19: real-time meta analysis of 6 studies page for the latest aggregate results). Moreover, ancillary investigations are examining the pharmacokinetics of high-dose bromhexine and ambroxol specifically for COVID-19, as well as the potential for combination with other repurposed agents such as doxycycline or ivermectin.
Beyond COVID-19, the TMPRSS2 inhibition strategy remains relevant for other coronaviruses and respiratory viruses that use similar entry mechanisms. Thus, the evidence amassed from the bromhexine trials could inform preparedness for future pandemics. For detailed study-level data and supplementary analyses, readers may visit the Supplementary Data — Bromhexine for COVID-19: real-time meta analysis of 6 studies page.
Conclusion
The real-time meta-analysis of five studies on bromhexine for COVID-19 provides a cautious but optimistic signal. While the current evidence does not justify definitive claims of efficacy, the trends toward clinical improvement, reduced severe outcomes, and excellent safety collectively support further investigation. In an era of evolving variants and persistent global health inequities, the potential of a low-cost, oral, host-directed repurposed drug like bromhexine cannot be overlooked. As the data evolve, this meta-analysis will serve as a critical resource for distilling the truth from the noise—one study at a time.